Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia

Am J Clin Oncol. 1995 Oct;18(5):382-4. doi: 10.1097/00000421-199510000-00003.

Abstract

Etoposide (125 mg/m2/d) and carboplatin (200 mg/m2/d) were administered by continuous 5-day intravenous infusion to 10 patients with relapsed or refractory acute leukemia (7 ANLL, 1 ALL, 2 blast crisis of CGL). No complete or partial response was observed despite dose-limiting toxicity characterized by severe diarrhea in four patients and neutropenic colitis in two additional cases. We cannot recommend the present schedule of drug administration for the treatment of acute leukemia.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Female
  • Humans
  • Infusions, Intravenous
  • Leukemia / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myeloid, Acute / drug therapy
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Salvage Therapy*

Substances

  • Etoposide
  • Carboplatin